Opus Genetics (IRD) Shareholder's Equity Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.16% |
| Dec 31, 2025 | 25.71% |
| Sep 30, 2025 | 21.37% |
| Jun 30, 2025 | 31.89% |
| Mar 31, 2025 | 21.05% |
| Dec 31, 2024 | 23.64% |
| Sep 30, 2024 | 23.88% |
| Jun 30, 2024 | 24.43% |
| Mar 31, 2024 | 23.64% |
| Dec 31, 2023 | 99.21% |
| Sep 30, 2023 | 50.97% |
| Jun 30, 2023 | 26.98% |
| Mar 31, 2023 | 22.47% |
| Dec 31, 2022 | 22.49% |
| Sep 30, 2022 | -4.71% |
| Jun 30, 2022 | -1.70% |
| Mar 31, 2022 | 72.54% |
| Dec 31, 2021 | 5.43% |
| Sep 30, 2021 | 3.59% |
| Jun 30, 2021 | 7.36% |
| Mar 31, 2021 | -10.62% |
| Dec 31, 2020 | -22.13% |
| Sep 30, 2020 | -20.41% |
| Jun 30, 2020 | -19.23% |
| Mar 31, 2020 | -18.76% |
| Dec 31, 2019 | -17.97% |
| Sep 30, 2019 | -16.29% |
| Jun 30, 2019 | -14.78% |
| Mar 31, 2019 | -10.68% |
| Dec 31, 2018 | -16.38% |
| Sep 30, 2018 | -8.23% |
| Jun 30, 2018 | 15.73% |
| Mar 31, 2018 | 12.32% |
| Dec 31, 2017 | 11.96% |
| Sep 30, 2017 | 26.13% |
| Jun 30, 2017 | 15.71% |
| Mar 31, 2017 | -33.46% |
| Dec 31, 2016 | 9.76% |
| Sep 30, 2016 | 11.13% |
| Jun 30, 2016 | 6.62% |
| Dec 31, 2015 | 12.55% |